Trial reportBlood advances2026
Patient and oncologist expectations of functional prognosis among older adults with acute myeloid leukemia.
Trial report in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05335369 (A Pilot Randomized Controlled Trial of a Patient-centered Communication Tool), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Randomized Controlled Trial of a Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
abstractAlthough older adults with cancer often prioritize maintaining physical function when making treatment decisions, whether patients and oncologists have similar expectations of future functioning remains unknown. We explored this among patients with acute myeloid leukemia (AML) and their oncologists in a pilot randomized controlled trial testing a decisional support tool (University of Rochester-Geriatric Oncology Assessment for Acute Myeloid Leukemia [UR-GOAL]). We included adults aged ≥60 years with newly diagnosed AML, randomized 1:1 to UR-GOAL (AML educational video, assessment of aging-related conditions, values, and prognostic awareness) or usual care (UC). After initiating treatment, patients and oncologists reported whether they expected the patient's physical function to decline, improve, or stay the same over the next 6 months and 1 year (functional prognosis). We estimated patient oncologist agreement using weighted κ statistics and evaluated differences by study arm. Of 100 enrolled patients, 77, who received care from 8 oncologists, responded to questions about the patient's functional prognosis. Patients had a mean age of 73 years (standard deviation, 6.8), and 39% were female. Fewer patients (15% at 6 months, 20% at 1 year) anticipated that their function would decline, compared with their oncologists (51% at 6 months, 54% at 1 year). Most patients (68%) had discordant expectations from their oncologist, with κ = 0.10 (6 months) and κ = 0.07 (1 year). However, clinically meaningful discordance (patient: maintain or improve; oncologist: decline) was less common among UR-GOAL patients vs UC (27% vs 56%; P = .010). Older adults with AML have expectations about their future physical function that differ from their oncologists. UR-GOAL may reduce this discordance. This trial was registered at www.ClinicalTrials.gov as NCT05335369.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.